India, April 29 -- HUTCHMED (China) Limited (HCM), a commercial-stage biopharmaceutical company, announced on Wednesday that the National Medical Product Administration (NMPA) of China has accepted the new drug application for Sovleplinib in treating warm autoimmune hemolytic anemia (wAIHA).
Autoimmune hemolytic anemia (AIHA) is a rare autoimmune disease characterized by the immune system lysing the body's own red blood cells (RBCs) through the production of antibodies. In cases of wAIHA, RBC destruction occurs at body temperature, and this is the most common form of AIHA.
Sovleplinib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (Sty), developed by HUTCHMED for the treatment of immunological diseases and haematol...